author-photo

Bradley Stringer

Takeda Pharmaceutical Company

8

Papers

194

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Abstract B120: TAK-164, a GCC-targeted antibody-drug conjugate (ADC) for the treatment of colorectal cancers and other GI malignancies

2018 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (5)
A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment

2018 Nature Medicine
Show All
- Source
- Cite
- Save
Citations (137)
Abstract B050: Evaluation of TAK-264, a novel antibody-drug conjugate in pancreatic cancer cell lines and patient-derived xenograft models

2018 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models

2018
Show All
- Source
- Cite
- Save
Citations (3)
Abstract 3916: Relationship of guanylyl cyclase C (GCC) expression and efficacy of TAK-164, a GCC-targeted antibody-drug conjugate in a panel of 68 subcutaneous HuPrime colorectal cancer PDX models

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism

2015 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (8)